Adrenas Therapeutics
BridgeBio Pharma is a biopharmaceutical company dedicated to discovering, creating, testing, and delivering transformative medicines for patients suffering from genetic diseases. Founded in 2015, it focuses on well-characterized genetic diseases and develops therapies at their source, leveraging scientific advancements and a decentralized corporate model to accelerate the development and delivery of medicines globally.
Industries
Nr. of Employees
small (1-50)
Adrenas Therapeutics
3160 Porter Drive, Suite 250, Palo Alto, CA, 94304
Patents
Products
Oral transthyretin stabilizer for ATTR cardiomyopathy (approved therapy)
Orally administered small-molecule TTR stabilizer indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with transthyretin-mediated cardiomyopathy.
cPMP substrate replacement therapy for MoCD Type A (regulatory submission-stage)
Cyclic pyranopterin monophosphate (cPMP) substrate replacement therapy developed to replace deficient substrate in molybdenum cofactor deficiency Type A and permit downstream enzyme activation.
Oral transthyretin stabilizer for ATTR cardiomyopathy (approved therapy)
Orally administered small-molecule TTR stabilizer indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with transthyretin-mediated cardiomyopathy.
cPMP substrate replacement therapy for MoCD Type A (regulatory submission-stage)
Cyclic pyranopterin monophosphate (cPMP) substrate replacement therapy developed to replace deficient substrate in molybdenum cofactor deficiency Type A and permit downstream enzyme activation.
Services
Insurance navigation, financial assistance, and dedicated support services to assist patients in accessing therapies.
Genetic testing and counseling service for eligible patients to detect variants in disease-associated genes to support diagnosis and study recruitment.
Insurance navigation, financial assistance, and dedicated support services to assist patients in accessing therapies.
Genetic testing and counseling service for eligible patients to detect variants in disease-associated genes to support diagnosis and study recruitment.
Expertise Areas
- Clinical trial management
- Gene therapy development
- Small-molecule drug discovery
- CMC and commercial manufacturing oversight
Key Technologies
- AAV9-based systemic gene therapy
- Small-molecule negative allosteric modulators (GPCR antagonists)
- Substrate replacement therapy chemistry
- Biomarker assays for urine/CSF/brain metabolites (e.g., NAA)
News & Updates
The FDA has accepted the NDA for fosdenopterin, a therapy for molybdenum cofactor deficiency Type A, granting Priority Review and marking BridgeBio’s first NDA acceptance.
The FDA has accepted the NDA for fosdenopterin for the treatment of MoCD Type A, granting Priority Review and making it BridgeBio’s first NDA acceptance.
The FDA has accepted the NDA for fosdenopterin, a therapy for molybdenum cofactor deficiency Type A, granting Priority Review and marking BridgeBio’s first NDA acceptance.
The FDA has accepted the NDA for fosdenopterin for the treatment of MoCD Type A, granting Priority Review and making it BridgeBio’s first NDA acceptance.